Clinical Trial Update: Twice-per-weekSelinexor, 2 Days Melphalan [Phase 3]

View source ↗

Summary

Phase 3 trial of twice-weekly selinexor with two days of melphalan for acute myeloid leukemia; study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Melphalan (Melphalan)
• Selinexor (selinexor)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: NOT_YET_RECRUITING